Literature DB >> 32035755

Race/Ethnicity and Sex-Related Differences in Direct Oral Anticoagulant Initiation in Newly Diagnosed Atrial Fibrillation: A Retrospective Study of Medicare Data.

Utibe R Essien1, Jared W Magnani2, Nemin Chen3, Walid F Gellad4, Michael J Fine4, Inmaculada Hernandez5.   

Abstract

BACKGROUND: Atrial fibrillation (AF) is the most common heart rhythm disorder and is associated with a 5-fold increased risk of ischemic stroke. Racial/ethnic minorities and women with AF have higher rates of stroke compared to white individuals and men respectively. Oral anticoagulation reduces the risk of stroke, yet prior research has described racial/ethnic and sex-based variation in its use. We sought to examine the initiation of any oral anticoagulant (warfarin or direct-acting oral anticoagulants, DOACs) by race/ethnicity and sex in patients with incident, non-valvular AF. Further in those who initiated any anticoagulant, we examined DOAC vs. warfarin initiation by race/ethnicity and sex.
METHODS: We used claims data from a 5% sample of Medicare beneficiaries to identify patients with incident AF from 2012 to 2014, excluding those without continuous Medicare enrollment. We used logistic regression to assess the association between race/ethnicity (white, black, Hispanic), sex, and oral anticoagulant initiation (any, warfarin vs. DOAC), adjusting for sociodemographics, medical comorbidities, stroke and bleeding risk.
RESULTS: The cohort of 42,952 patients with AF included 17,935 women, 3282 blacks, and 1958 Hispanics. Overall OAC initiation was low (49.2% whites, 48.1% blacks, 47.5% Hispanics, 48.1% men, and 51.5% women). After adjusting, blacks (odds ratio (OR) 0.84; 95% CI, 0.78-0.91) were less likely than whites to initiate any oral anticoagulant with no difference observed between Hispanics and whites (OR 0.92; 95% CI, 0.83-1.01). Women were less likely than men to initiate any oral anticoagulant, OR 0.59 (95% CI 0.55-0.64). Among initiators of oral anticoagulation, DOAC use was low (35.8% whites, 29.3% blacks, 40.0% Hispanics, 41.6% men, and 42.4% women). After adjusting, blacks were less likely to initiate DOACs than whites, OR 0.75 (95% CI 0.66-0.85); the odds of DOAC initiation did not differ between Hispanic and white patients or between men and women.
CONCLUSION: In a national cohort of Medicare beneficiaries with newly-diagnosed AF, overall oral anticoagulant initiation was lower in blacks and women, with no difference observed by Hispanic ethnicity. Among oral anticoagulant initiators, blacks were less likely to initiate novel DOACs, with no differences identified by Hispanic ethnicity or sex. Identifying modifiable causes of treatment disparities is needed to improve quality of care for all patients with AF. Published by Elsevier Inc.

Entities:  

Keywords:  Anticoagulation; Atrial fibrillation; Disparities; Gender; Race/ethnicity

Mesh:

Substances:

Year:  2020        PMID: 32035755      PMCID: PMC7183759          DOI: 10.1016/j.jnma.2019.10.003

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  17 in total

Review 1.  Review of race/ethnicity in non vitamin K antagonist oral anticoagulants clinical trials.

Authors:  Larry R Jackson; Eric D Peterson; Eze Okeagu; Kevin Thomas
Journal:  J Thromb Thrombolysis       Date:  2015-02       Impact factor: 2.300

2.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.

Authors:  Ron Pisters; Deirdre A Lane; Robby Nieuwlaat; Cees B de Vos; Harry J G M Crijns; Gregory Y H Lip
Journal:  Chest       Date:  2010-03-18       Impact factor: 9.410

Review 3.  Registries in Atrial Fibrillation: From Trials to Real-Life Clinical Practice.

Authors:  Michał Mazurek; Menno V Huisman; Gregory Y H Lip
Journal:  Am J Med       Date:  2016-10-13       Impact factor: 4.965

4.  Relation of gender-specific risk of ischemic stroke in patients with atrial fibrillation to differences in warfarin anticoagulation control (from AFFIRM).

Authors:  Renee M Sullivan; Jingyang Zhang; Gideon Zamba; Gregory Y H Lip; Brian Olshansky
Journal:  Am J Cardiol       Date:  2012-09-18       Impact factor: 2.778

5.  Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation.

Authors:  Inmaculada Hernandez; Yuting Zhang; Samir Saba
Journal:  Am J Cardiol       Date:  2017-08-08       Impact factor: 2.778

6.  Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II.

Authors:  Utibe R Essien; DaJuanicia N Holmes; Larry R Jackson; Gregg C Fonarow; Kenneth W Mahaffey; James A Reiffel; Benjamin A Steinberg; Larry A Allen; Paul S Chan; James V Freeman; Rosalia G Blanco; Karen S Pieper; Jonathan P Piccini; Eric D Peterson; Daniel E Singer
Journal:  JAMA Cardiol       Date:  2018-12-01       Impact factor: 14.676

7.  Adherence to Guideline-Directed Stroke Prevention Therapy for Atrial Fibrillation Is Achievable.

Authors:  Jonathan P Piccini; Haolin Xu; Margueritte Cox; Roland A Matsouaka; Gregg C Fonarow; Javed Butler; Anne B Curtis; Nihar Desai; Margaret Fang; Pamela J McCabe; Robert L Page Ii; Mintu Turakhia; Andrea M Russo; Bradley P Knight; Mandeep Sidhu; Jodie L Hurwitz; Kenneth A Ellenbogen; William R Lewis
Journal:  Circulation       Date:  2019-03-19       Impact factor: 29.690

8.  Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry.

Authors:  Harsh Golwala; Larry R Jackson; DaJuanicia N Simon; Jonathan P Piccini; Bernard Gersh; Alan S Go; Elaine M Hylek; Peter R Kowey; Kenneth W Mahaffey; Laine Thomas; Gregg C Fonarow; Eric D Peterson; Kevin L Thomas
Journal:  Am Heart J       Date:  2015-12-30       Impact factor: 4.749

9.  Relative contribution of modifiable risk factors for incident atrial fibrillation in Hispanics, African Americans and non-Hispanic Whites.

Authors:  Eric Shulman; Jay J Chudow; Utibe R Essien; Anusha Shanbhag; Faraj Kargoli; Jorge Romero; Luigi Di Biase; John Fisher; Andrew Krumerman; Kevin J Ferrick
Journal:  Int J Cardiol       Date:  2018-10-10       Impact factor: 4.164

10.  Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke: Findings From the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study.

Authors:  Ying Xian; Haolin Xu; Emily C O'Brien; Shreyansh Shah; Laine Thomas; Michael J Pencina; Gregg C Fonarow; DaiWai M Olson; Lee H Schwamm; Deepak L Bhatt; Eric E Smith; Deidre Hannah; Lesley Maisch; Barbara L Lytle; Eric D Peterson; Adrian F Hernandez
Journal:  JAMA Neurol       Date:  2019-10-01       Impact factor: 18.302

View more
  10 in total

1.  Prescribing of anticoagulation for atrial fibrillation in primary care.

Authors:  Kathryn A Martinez; Mark H Eckman; Matthew A Pappas; Michael B Rothberg
Journal:  J Thromb Thrombolysis       Date:  2022-04-21       Impact factor: 2.300

2.  Association of Neighborhood Disadvantage and Anticoagulation for Patients with Atrial Fibrillation in the Veterans Health Administration: the REACH-AF Study.

Authors:  Annie McDermott; Nadejda Kim; Leslie R M Hausmann; Jared W Magnani; Chester B Good; Terrence M A Litam; Maria K Mor; Toluwa D Omole; Walid F Gellad; Michael J Fine; Utibe R Essien
Journal:  J Gen Intern Med       Date:  2022-09-23       Impact factor: 6.473

3.  Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation Treatment: Rural and Urban Trends in Medicare Beneficiaries.

Authors:  Faye L Norby; Pamela L Lutsey; Nathan D Shippee; Lin Y Chen; Carrie Henning-Smith; Alvaro Alonso; Rob F Walker; Aaron R Folsom
Journal:  Am J Cardiovasc Drugs       Date:  2021-10-11       Impact factor: 3.283

4.  Anticoagulant Prescriptions Provided in US Ambulatory Practice, 2014 to 2016.

Authors:  Tali Azenkot; Brittany Chatterton; Eleanor Bimla Schwarz
Journal:  J Gen Intern Med       Date:  2022-04-11       Impact factor: 6.473

5.  Sex differences in atrial fibrillation: patient-reported outcomes and the persistent toll on women.

Authors:  Raisa L Silva; Emily N Guhl; Andrew D Althouse; Brandon Herbert; Michael Sharbaugh; Utibe R Essien; Leslie R M Hausmann; Jared W Magnani
Journal:  Am J Prev Cardiol       Date:  2021-09-03

6.  Incidence and Predictors of Primary Nonadherence to Sodium Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Agonists in a Large Integrated Healthcare System.

Authors:  Jing Luo; Robert Feldman; Scott Rothenberger; Mary Korytkowski; Michael A Fischer; Walid F Gellad
Journal:  J Gen Intern Med       Date:  2022-01-19       Impact factor: 6.473

7.  Choice of oral anticoagulant prescribed by general practices in Wales: Application of Dirichlet regression and linked data.

Authors:  Daniel Hill-McManus; Dyfrig A Hughes
Journal:  Br J Clin Pharmacol       Date:  2022-01-25       Impact factor: 3.716

8.  Impact of social determinants of health on anticoagulant use among patients with atrial fibrillation: Systemic review and meta-analysis.

Authors:  Rasha Khatib; Nicole Glowacki; John Byrne; Peter Brady
Journal:  Medicine (Baltimore)       Date:  2022-09-02       Impact factor: 1.817

Review 9.  Social determinants of atrial fibrillation.

Authors:  Utibe R Essien; Jelena Kornej; Amber E Johnson; Lucy B Schulson; Emelia J Benjamin; Jared W Magnani
Journal:  Nat Rev Cardiol       Date:  2021-06-02       Impact factor: 32.419

10.  Disparities in Anticoagulant Therapy Initiation for Incident Atrial Fibrillation by Race/Ethnicity Among Patients in the Veterans Health Administration System.

Authors:  Utibe R Essien; Nadejda Kim; Leslie R M Hausmann; Maria K Mor; Chester B Good; Jared W Magnani; Terrence M A Litam; Walid F Gellad; Michael J Fine
Journal:  JAMA Netw Open       Date:  2021-07-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.